Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT06685354
- Locations
- 🇨🇳
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
ARX788 in HER2-positive Metastatic Breast Cancer Patients
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06663748
Evaluating High-dose Furmonertinib With Bevacizumab and Pemetrexed for EGFRm NSCLC With Leptomeningeal Metastasis
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06643000
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Local Injection and Systemic Therapy in the Treatment of NSCLC.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT06618391
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-09-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06605521
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06598046
- Locations
- 🇨🇳
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT06586697
- Locations
- 🇨🇳
HenanCH, Zhengzhou, Henan, China
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06554028
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06545201
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06546150
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath